

BEST AVAILABLE COPY

PTO.SB/08A (04-03)

Approved for use through 04/30/03. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/776,568
Filing Date	February 10, 2004
First Named Inventor	Carolyn Petersen, et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25699A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
LW	AA	5,484,926	02-16-1996	Agouron Pharmaceuticals, Inc.	
↓	AB	5,952,343	09-14-1999	Agouron Pharmaceuticals, Inc.	
↓	AC	6,162,812	12-19-2000	Agouron Pharmaceuticals, Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ Number ⁴ Kind Code ⁵ (if known)				

EXAMINER:

[Signature]

DATE CONSIDERED:

10/24/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/776,568
Filing Date	February 10, 2004
First Named Inventor	Carolyn Petersen, et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25699A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LW	AD	AARNOUTSE, R.E., et al., "Pharmacokinetics, Food Intake Requirements and Tolerability of Once-Daily Combinations of Nelfinavir and Low-Dose Ritonavir in Healthy Volunteers," <i>Br J Clin Pharmacol</i> , 2002, 115-125, Vol. 55.	
	AE	BURGER, David M., et al., "Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) 1250 mg BID in Treatment-Naïve Patients Improves Therapeutic Outcome After 1 Year; Result from Athena," <i>2nd International Workshop on Clinical Pharmacology of HIV Therapy</i> , 2001, Abstract 6.2b, The Netherlands.	
	AF	KUROWSKI, M., et al., "Limited Effect of Food Composition on the Pharmacokinetics of Nelfinavir Administered Twice Daily," <i>Eur J. Med. Res.</i> , 2002, 453-456, Vol. 7.	
	AG	LENHARD, James M., et al., "Dietary Fat Alters HIV Protease Inhibitor-Induced Metabolic Changes in Mice," <i>American Society for Nutritional Sciences</i> , 2000, 2361-2366.	
	AH	PHYSICIAN'S DESK REFERENCE (PDR) "Entry for Viracept nelfinavir," 2001.	
	AI	PETERSEN, C., et al., "Pharmacokinetics of Nelfinavir (Viracept 250 mg tablet): Effect of Food Intake on Single-dose PK Parameters," <i>10th Conference on Retroviruses and Opportunistic Infections Abstract 544</i> , 2003, Boston, MA.	
	AJ	QUART, BD, et al., "Phase I Safety, Tolerance, Pharmacokinetics and Food Effect Studies of AG1343 - a Novel Protease Inhibitor," <i>Natl Conf Hum Retroviruses Relat Infect (2nd)</i> , 1995, 167.	
✓	AK	SHETTY, Bhasker V., et al., "Preclinical Pharmacokinetics and Distribution to Tissue of AG1343, an Inhibitor of Human Immunodeficiency Virus Type 1 Protease," <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 110-114, Vol. 40, No. 1.	

EXAMINER:

DATE CONSIDERED:

10/24/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/776,568
Filing Date	February 10, 2004
First Named Inventor	Carolyn Petersen
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC25699A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
LW		WO 98/22106	05-28-1998	Abbott Laboratories		
LW		WO 99/25352	05-27-1999	Merck & Co., Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LW		FLEXNER, C., "HIV-Protease Inhibitors," Drug Therapy, 1998, 1281-1292, vol. 338, no. 18.	

EXAMINER:

DATE CONSIDERED:

10/21/2005

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.